PZ Cormay SA
WSE:CRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (16), the stock would be worth zł-0.38 (165% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -24.7 | zł0.59 |
0%
|
| Industry Average | 16 | zł-0.38 |
-165%
|
| Country Average | 11.3 | zł-0.27 |
-146%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
P
|
PZ Cormay SA
WSE:CRM
|
50m PLN | -24.7 | -12 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60.7B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.6T JPY | 33.6 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 28 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 15 | 23.6 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD | 19.9 | 33.2 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.4B GBP | 18.1 | 33.2 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 54.4 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
880.1B JPY | 32.4 | 50.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.9T KRW | -76.3 | -36 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 18 | 22.9 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 8.1 |
| Median | 11.3 |
| 70th Percentile | 16 |
| Max | 313.7 |
Other Multiples
PZ Cormay SA
Glance View
PZ Cormay SA engages in the manufacture of diagnostic reagents and laboratory equipment. The company is headquartered in Lomianki, Woj. Mazowieckie and currently employs 218 full-time employees. The company went IPO on 2008-08-20. The firm is engaged in the design, manufacture and distribution of a range of products for clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation and specific protein recognition. The company offers drugs, biochemical rapid tests and devices such as vacuettes and tubes. PZ Cormay SA provides also biochemical analyzers: ACCENT-300, ACCENT-200, PRESTIGE 24i and LIVIA; hematological analyzers: MYTHIC 18, among others, and urinalysis apparatus: IChem 100. On September 1, 2014, Orphee SA acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee SA.
